Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
PR Newswire
RADNOR, Pa.
,
June 2, 2021
/PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) investors that the firm has filed a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock
between
April 24, 2020
, and
April 16, 2021
, inclusive (the “Class Period”). This action, captioned
Roth v. Emergent BioSolutions Inc., et al.
, Case No. 1:21-cv-01189-PX (the ”
Roth
Action”), was filed in
the United States
District Court for the District of
Maryland
(Southern Division). To view a copy of the
Roth
Action complaint,
please click here.
Lead Plaintiff Deadline:
June 18, 2021
Contact:
James Maro, Esq.
(484) 270-1453
Adrienne Bell, Esq.
(484) 270-1435
Toll free (844) 887-9500
Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases.
The
Roth
Action alleges that, throughout the Class Period, the defendants failed to disclose that: (1) Emergent’s
Baltimore
facility had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) the
Baltimore
facility had received a series of Food and Drug Administration (“FDA”) citations as a result of these contamination risks and quality control issues; (3) Emergent had been forced to discard millions of doses of COVID-19 vaccines after workers at the facility deviated from manufacturing standards; and (4) as a result of the foregoing, the defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its
Baltimore
facility were materially false and/or misleading and/or lacked a reasonable basis.
Emergent
investors may,
no later than
June 18, 2021
, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from
the United States
and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP please visit
www.ktmc.com
.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA
19087
(844) 887-9500 (toll free)
[email protected]
View original content to download multimedia:
http://www.prnewswire.com/news-releases/investor-reminder–kessler-topaz-meltzer–check-llp-reminds-investors-of-deadline-in-securities-fraud-class-action-lawsuit-filed-against-emergent-biosolutions-inc-301304295.html
SOURCE Kessler Topaz Meltzer & Check, LLP
